**Author details**

Joanne W. Chiu

Address all correspondence to: jwychiu@hku.hk

Department of Medicine, Medical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong

[10] Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Research and Treatment.

Management of Hormone Receptor-Positive Metastatic Breast Cancer

http://dx.doi.org/10.5772/intechopen.75759

175

[11] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast

[12] Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphoryla-

[13] Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant

[14] Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research.

[15] Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after

[16] Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Research and Treatment.

[17] Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast

[18] Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hor-

[19] Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Research. 2004;

[20] Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with

[21] Fu X, Osborne CK, Schiff R. Biology and therapeutic potential of PI3K signaling in ER+/

[22] Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone

PTEN loss in human breast carcinoma. Cancer Research. 2005;**65**(7):2554-2559

HER2-negative breast cancer. Breast. 2013;**22**(Suppl 2):S12-S18

mone dependence in breast cancer. Cancer Research. 2011;**71**(21):6773-6784

neoadjuvant letrozole. Journal of Clinical Oncology. 2006;**24**(19):3019-3025

1998;**52**(1-3):1-15

2009;**11**(5):R77

2009;**114**(2):263-275

**64**(21):7678-7681

tumours. Nature. 2012;**490**(7418):61-70

tion. Molecular Endocrinology. 1995;**9**(12):1804-1813

cancer. Cancer Research. 2010;**70**(5):2085-2094

breast cancer. Endocrine-Related Cancer. 2011;**18**(3):333-345
